CEL-SCI completes Breakthrough Medicine Designation application for Multikine

CEL-SCI (CVM) announced it has completed its Breakthrough Medicine Designation application for Multikine for submission to the Saudi Food and Drug Authority in Saudi Arabia. Multikine is an immunotherapy administered before surgery as a treatment for newly diagnosed previously untreated head and neck cancer. The Breakthrough Designation Application is expected to be formally submitted to the SFDA on CEL-SCI’s behalf within the next few weeks by the Company’s prospective Saudi partner, one of the country’s premier pharmaceutical and healthcare companies. According to the SFDA, the response time to a Breakthrough Medicine Designation application is approximately 60 days.